Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Director | June 05, 2018 | June 07, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Spero Therapeutics, Inc.
Report date June 05, 2018 · Filed June 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.54 · Expires 2028-06-05 | Direct | 6,073 |
Reported balance
After 2018-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-05 · Grant · Acquired 6,073 · Balance 6,073 F1: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2018 Filed Jun 7, 2018 00:01 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0000899243-18-015327 · doc4.xml · derivative · entry 1 Breum Casper · CIK 0001630850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2028-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | ConversionSeries C Preferred Stock · Derivative | 2,485,272 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-025505 · doc4.xml · derivative · entry 7 Breum Casper · CIK 0001630850 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Lundbeckfond Invest A/S Disclosed balance after: 0 Underlying: Common Stock · 408,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F2 · derivative.exercise_date: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F2 · derivative.expiration_date: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F3 · ownership.nature: Shares held by Lundbeckfond Invest A/S. The Reporting Person shares voting and investment power with respect to the shares held by Lundbeckfond Invest A/S and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | ConversionSeries B Preferred Stock · Derivative | 681,818 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-025505 · doc4.xml · derivative · entry 6 Breum Casper · CIK 0001630850 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Lundbeckfond Invest A/S Disclosed balance after: 0 Underlying: Common Stock · 179,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F2 · derivative.exercise_date: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F2 · derivative.expiration_date: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F3 · ownership.nature: Shares held by Lundbeckfond Invest A/S. The Reporting Person shares voting and investment power with respect to the shares held by Lundbeckfond Invest A/S and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | ConversionSeries A Preferred Stock · Derivative | 1,153,846 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-025505 · doc4.xml · derivative · entry 5 Breum Casper · CIK 0001630850 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Lundbeckfond Invest A/S Disclosed balance after: 0 Underlying: Common Stock · 289,102 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F2 · derivative.exercise_date: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F2 · derivative.expiration_date: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F3 · ownership.nature: Shares held by Lundbeckfond Invest A/S. The Reporting Person shares voting and investment power with respect to the shares held by Lundbeckfond Invest A/S and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | PurchaseCommon Stock | 214,285 | $14.00 | $2,999,990.00 |
DisclosureSEC source: 0000899243-17-025505 · doc4.xml · nonDerivative · entry 4 Breum Casper · CIK 0001630850 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Lundbeckfond Invest A/S Disclosed balance after: 1,091,774 F1 · shares: Reflects shares of the Issuer's common stock that were purchased in connection with the Issuer's initial public offering. F3 · ownership.nature: Shares held by Lundbeckfond Invest A/S. The Reporting Person shares voting and investment power with respect to the shares held by Lundbeckfond Invest A/S and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | ConversionCommon Stock | 408,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-025505 · doc4.xml · nonDerivative · entry 3 Breum Casper · CIK 0001630850 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Lundbeckfond Invest A/S Disclosed balance after: 877,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F3 · ownership.nature: Shares held by Lundbeckfond Invest A/S. The Reporting Person shares voting and investment power with respect to the shares held by Lundbeckfond Invest A/S and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | ConversionCommon Stock | 179,450 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-025505 · doc4.xml · nonDerivative · entry 2 Breum Casper · CIK 0001630850 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Lundbeckfond Invest A/S Disclosed balance after: 468,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F3 · ownership.nature: Shares held by Lundbeckfond Invest A/S. The Reporting Person shares voting and investment power with respect to the shares held by Lundbeckfond Invest A/S and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| November 06, 2017 Filed Nov 7, 2017 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | ConversionCommon Stock | 289,102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-025505 · doc4.xml · nonDerivative · entry 1 Breum Casper · CIK 0001630850 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Lundbeckfond Invest A/S Disclosed balance after: 289,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date. F3 · ownership.nature: Shares held by Lundbeckfond Invest A/S. The Reporting Person shares voting and investment power with respect to the shares held by Lundbeckfond Invest A/S and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.